HCV Archives – Page 18 of 31 – Treatment Action Group

Treatment Action Group Welcomes Hepatitis C Virus (HCV) Project Co-Directors Annette Gaudino and Bryn Gay

June 16, 2016
Chad Cipiti

Today Treatment Action Group (TAG) welcomes incoming Hepatitis C Virus (HCV) Project Co-Directors Annette Gaudino and Bryn Gay. Annette begins at TAG today and Bryn on June 20.

Hepatitis C: No More Treatment Rationing; Universal Access to Generic Medicines Everywhere!

April 16, 2016
Chad Cipiti

People with hepatitis C virus (HCV) and their allies from Spain and around the world have gathered at the International Liver Congress to protest the outrageous price of life-saving HCV medicines. They are pushing for generic competition to bring down the price of HCV treatment and ensure universal access.

Zepatier Fact Sheet

April 12, 2016
Chad Cipiti

Zepatier is two hepatitis C virus-fighting drugs in one tablet. These drugs block different steps of the virus lifecycle. In the United States, Zepatier is approved for people who are over 18 years old with hepatitis C genotype 1 or genotype 4.

Solvaldi Fact Sheet

April 2, 2016
Chad Cipiti

Sovaldi (sofosbuvir) is an HCV-fighting drug that must be used with other drugs. In the United States, Sovaldi is approved for people with hepatitis C genotypes 1, 2, 3, or 4 who are over 18 years old.

Harvoni Fact Sheet

April 2, 2016
Chad Cipiti

Harvoni is two HCV-fighting drugs (sofosbuvir and ledipasvir) in one pill. In the United States, Harvoni is approved for HIV-negative and HIV-positive people with hepatitis C genotypes 1, 4, 5, and 6 who are over 18 years old.

The Low Cost of Universal Access

April 1, 2016
Chad Cipiti

Generic treatments for HIV, viral hepatitis, and cancer can be affordably—and profitably—mass-produced for broad, unobstructed availability By Tracy Swan TAG talks with Andrew Hill, senior visiting research fellow in the University of Liverpool’s Department of Pharmacology, about his group’s work…

Greed and the Necessity for Regulation

April 1, 2016
Chad Cipiti

The story of U.S. drug pricing run amok isn’t just about corporate arrogance and avarice—it is also about government permissiveness and inaction By Tim Horn, Erica Lessem, and Kenyon Farrow On December 1, 2015, the U.S. Senate Finance Committee issued…

mapCrowd: an online data collection platform for hepatitis C information

February 8, 2016
Chad Cipiti

Médecins du Monde (MdM) and Treatment Action Group (TAG) are pleased to announce the launch of mapCrowd (www.mapCrowd.org), an innovative online resource and data collection platform for gathering and sharing hepatitis C information.

2015 TAG Update

December 10, 2015
Chad Cipiti

TAG’s annual review of progress we’ve made on the the fight to end HIV/AIDS, Viral Hepatitis, and Tuberculosis.

HCV Global Access Webinars Series

December 8, 2015
Chad Cipiti

December 8, 2015 DOWNLOAD: HCV Webinar #1: The Cost of Production for HCV Treatment Slides Presenter: Dr. Andrew Hill, Senior Research Fellow, Department of Pharmacology and Therapeutics, Liverpool University, United Kingdom Description: New HCV drugs, called direct-acting antivirals (DAAs),…